With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Headline: PARP inhibition proves to be the first successful biomarker-driven systemic therapy for pancreatic cancer. The POLO trial enrolled 151 patients with germline BRCA-mutations and metastatic pancreatic cancer not progressing after at least 16 weeks of platinum chemo. They were then randomized to maintenance PARP inhibition with oral olaparib versus placebo. As predicted (with help), maintenance olaparib nearly doubled median progression-free survival from 3.8 → 7.4 months. TBL: This won’t impact a terribly large amount of people, but it’s another clinical win for the theoretical effectiveness of PARP inhibition in the setting of BRCA-aberrations. | Golan, N Engl J Med 2019